TiumBio Co., Ltd.
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
321550 | KO
Overview
Corporate Details
- ISIN(s):
- KR7321550006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
- Website:
- http://www.tiumbio.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
TiumBio Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutics for rare and incurable diseases. The company leverages its expertise in both small-molecule synthetic drugs and biologics to build a robust pipeline targeting areas with high unmet medical needs and significant growth potential. Its lead clinical programs include Merigolix (TU2670), an oral GnRH antagonist for treating gynecological conditions like endometriosis and uterine fibroids, and TU7710, a long-acting recombinant protein for hemophilia. Founded in 2016, TiumBio is also expanding its R&D capabilities into next-generation therapies, including bispecific antibodies and antibody-drug conjugates (ADCs), to create market value through its distinct portfolio.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.8 MB | ||
| 2025-07-22 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.6 KB | ||
| 2025-07-07 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 28.8 KB | ||
| 2025-05-27 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (혈우병 치료신약 TU7710의 아르메니아 임상 1b상 시험계획(IN…
|
Korean | 12.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.0 MB | ||
| 2025-04-28 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 27.1 KB | ||
| 2025-04-28 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 149.4 KB | ||
| 2025-04-28 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 168.5 KB | ||
| 2025-04-23 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-03-27 00:00 |
Post-Annual General Meeting Information
정기주주총회결과
|
Korean | 24.3 KB | ||
| 2025-03-27 00:00 |
Capital/Financing Update
증권발행결과(자율공시)
|
Korean | 6.2 KB | ||
| 2025-03-24 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(교환사채권발행결정)
|
Korean | 36.5 KB | ||
| 2025-03-24 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.5 KB | ||
| 2025-03-20 00:00 |
Regulatory News Service
투자판단관련주요경영사항 (호흡기질환 치료제 개발 프로그램 NCE401 기술이전 계약해지 및 권리 반환)
|
Korean | 6.2 KB | ||
| 2025-03-20 00:00 |
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
|
Korean | 45.7 KB |
Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TiumBio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
